MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Q1 2026 Positive Adjusted EBITDA(1) Net Revenue of $9M with strong gross margins of 37% OPEX decreased 28% in Q1 2026 versus Q4 2025 Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities Management to Host Conference Call / Webcast on May 13th,... The post MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA appeared first on Montreal Gazette .

Original source: Montreal Gazette